Acme United Earnings Call Transcripts
Fiscal Year 2026
-
The company is focusing on expanding its first aid and safety segment, which offers higher growth and recurring revenue, while maintaining leadership in cutting solutions. Recent acquisitions like My Medic enhance direct-to-consumer reach and international expansion is underway, with a goal of reaching $300M in revenue within three years.
-
The meeting covered board elections, an increase in stock options, executive pay, and auditor ratification, with all proposals approved by majority vote. No shareholder questions were raised during the Q&A session.
-
Net sales grew 14% year-over-year to $52.3 million, driven by acquisitions, but net income fell 40% due to tariffs and higher SG&A. Gross margin improved to 39.7%, and cost pressures are expected to ease in coming quarters.
Fiscal Year 2025
-
Record 2025 sales and earnings were driven by strong first aid and medical growth, strategic acquisitions, and operational investments, despite tariff and supply chain challenges. Outlook for 2026 is positive, with further expansion in direct-to-consumer and retail channels.
-
Q3 2025 saw 2% revenue growth and strong first aid sales, but net income fell 14% due to higher taxes. Gross margin improved to 39.1%, and a new facility will boost capacity in 2026. Tariff volatility and supply chain risks remain key challenges.
-
Record Q2 earnings achieved despite a 3% sales decline, driven by strong cost controls and supply chain shifts amid 145% tariffs. Net income rose 7% to $4.8 million, with growth expected in the second half as delayed orders recover.
-
Q1 2025 saw 2% sales growth and 5% EPS increase, led by first-aid and automation gains. Tariff volatility and supply chain risks persist, but diversified sourcing and productivity initiatives support resilience. Acquisition opportunities are being actively pursued.
-
Strong liquidity and record earnings support ongoing innovation in first aid and cutting tools, with RFID-enabled kits and automation driving growth. Strategic acquisitions and proactive tariff management position the business for continued expansion and resilience.
Fiscal Year 2024
-
Record 2024 net sales and EBITDA were achieved, with net income up 23% year-over-year. Strong growth in first-aid and cutting tools offset the impact of divestitures, while productivity gains and diversified sourcing position the company well for tariff challenges in 2025.
-
Strong organic growth and strategic acquisitions have driven revenue to nearly $200 million, with a focus on high-margin first aid and cutting products. Innovation in automated first aid kits and disciplined financial management support ambitious targets for $300 million revenue in three years.
-
Record 2024 sales of $200 million are driven by strategic acquisitions, product innovation, and automation, with EBITDA expected to exceed $20 million. Supply chain diversification to Southeast Asia is underway to mitigate tariffs and reduce costs.
-
Q3 2024 sales declined 4% year-over-year due to a divestiture, but net income rose 3%. Excluding the sold business, sales grew 4%, with strong performance in Westcott and DMT. Management expects continued strong earnings and is actively mitigating tariff risks.
-
Q2 2024 saw 4% sales growth and a 29% net income increase, with gross margin up to 40.8%. Excluding divested lines, organic sales rose 8%, and recent acquisitions are driving expansion and operational improvements.